Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.

Scott Gottlieb

Former US Food and Drug Administration commissioner Scott Gottlieb's primary focus on chimeric antigen receptor T-cell (CAR-T) products when he was head of the agency involved ensuring such products were safe and effective. Now in his post-commissioner life, it appears he will be broadening his attention even further to include their reimbursement.

Speaking on 10 May at the National Press Club in one of his first public addresses since leaving the agency,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet